Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that Executive Chairman William
Doyle will present at the New
York Academy of Sciences’ 13th Key Symposium 2016: Bioelectronic
Medicine – Technology Targeting Molecular Mechanisms on Friday,
Sept. 23, 2016. Mr. Doyle’s presentation “Tumor Treating Fields – A
Novel Cancer Therapy Utilizing Alternating Electric Fields” will focus
on Novocure’s innovative treatment for solid tumors.

The symposium brings together thought leaders of bioelectronic medicine,
which NYAS describes as the epicenter of where healthcare, technology
and science converge and a science that may change the future of
therapies for a wide variety of diseases.

“I am honored to share the science of Tumor Treating Fields (TTFields)
at this prestigious event,” Mr. Doyle said. “Treatment with TTFields
significantly prolongs survival of patients with newly diagnosed
glioblastoma without the cancer therapy side effects that commonly
compromise quality of life. We are committed to bringing TTFields
therapy to GBM patients and to advancing our clinical pipeline in other
solid tumor cancers.”

About Novocure

Novocure is a commercial-stage oncology company developing a novel,
proprietary therapy called Tumor Treating Fields, or TTFields, for the
treatment of solid tumor cancers. Headquartered in Jersey, Novocure
has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania,
and New York City. Additionally, the company has offices
in Germany, Switzerland and Japan, and a research center in Haifa,
Israel. For additional information about the company, please visit www.novocure.com or
follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, development of potential
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects
for its products, and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as « anticipate, »
« estimate, » « expect, » « project, » « intend, » « plan, » « believe » or other
words and terms of similar meaning. Novocure’s performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and
Exchange Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements.
Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160915005067/en/